SteelPeak Wealth LLC Has $1.93 Million Holdings in Cencora, Inc. (NYSE:COR)

SteelPeak Wealth LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 72.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,594 shares of the company’s stock after purchasing an additional 3,604 shares during the quarter. SteelPeak Wealth LLC’s holdings in Cencora were worth $1,934,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Kingswood Wealth Advisors LLC acquired a new position in Cencora during the 2nd quarter valued at $655,000. TD Asset Management Inc bought a new stake in Cencora in the 1st quarter valued at $95,313,000. LSV Asset Management bought a new stake in Cencora in the 1st quarter valued at $3,579,000. Lake Street Advisors Group LLC bought a new stake in Cencora in the 1st quarter valued at $836,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Cencora in the 1st quarter valued at $15,632,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wells Fargo & Company boosted their price target on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Robert W. Baird lowered their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Finally, Evercore ISI lowered their target price on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $259.44.

Cencora Stock Down 1.0 %

Shares of NYSE:COR opened at $229.47 on Thursday. Cencora, Inc. has a 12 month low of $182.75 and a 12 month high of $247.66. The company’s 50-day moving average price is $231.91 and its two-hundred day moving average price is $230.73. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The firm has a market cap of $45.22 billion, a P/E ratio of 24.92, a P/E/G ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same quarter in the prior year, the firm earned $2.92 EPS. The company’s revenue was up 10.8% on a year-over-year basis. As a group, research analysts forecast that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.